Navigation Links
Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
Date:11/5/2010

CAMBRIDGE, Mass., Nov. 5, 2010 /PRNewswire/ -- Pervasis Therapeutics, Inc. today announced that it has been awarded over $920,000 in grants through the U.S. government's Qualifying Therapeutic Discovery Project, which provides tax credits and grants to projects that show significant potential to produce new therapies, reduce long-term health care costs, or significantly advance the goal of curing cancer within the next 30 years.  

Pervasis is a clinical stage company focused on developing breakthrough therapies with the potential to improve outcomes following common vascular surgical and interventional procedures, such as arteriovenous access, angioplasties, stents and peripheral and coronary bypass grafts—the failure of which result in serious complications and a significant increase in medical costs. There are no currently approved therapies that directly target the underlying physiological processes leading to serious vascular complications, including inflammation, thrombosis (the formation of a blood clot inside a blood vessel) and restenosis (the re-narrowing of a coronary artery after it has been treated with angioplasty or stenting).

Pervasis' therapies harness the power of the endothelium, the thin layer of cells that lines the interior surface of blood vessels, which has a well-understood role in regulating many of the body's healing processes, including vascular repair. Because these endothelial formulations secrete several key factors involved in combating inflammation and restenosis, they may also be applicable to other therapeutic fields where surgical or interventional procedures are required, including inflammatory disease, orthopedic injury and cancer.

The grants awarded to Pervasis span several therapeutic fields for which the company's therapies have application including:

  • Development of PVS-10200 for Peripheral Artery Disease ($244,479.25)
  • Development of Vascugel® to Sustain Arteriov
    '/>"/>

  • SOURCE Pervasis Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
    2. Nektar Therapeutics Reports Third Quarter 2010 Financial Results
    3. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
    4. Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
    5. Talecris Biotherapeutics Launches PROLASTIN®-C in Canada
    6. Cell Therapeutics Awarded $977,917 in Grants Under the Therapeutic Discovery Tax Credit Program
    7. Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
    8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
    9. Shield Therapeutics Signs Agreement With AOP Orphan for ST10-021
    10. Echo Therapeutics to Present at the LifeTech Capital 1st Annual Miami Medical Investors Conference
    11. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... Aug. 29, 2014 Research and Markets  has ... Pipeline Insight 2014" report to their offering. ... is one of the largest segments of pharmaceuticals industry. The ... while the available therapies were unable to meet the market ... market for CNS disorder, especially over the past two decades. ...
    (Date:8/29/2014)... , Aug. 29, 2014 Research ... "Research and Development Trend Forecast of Pharmaceutical Equipment ... Research and Development Trend Forecast of ... 2014-2018 mainly analyzes China,s pharmaceutical ... supply & demand, competition landscape, and business performance of ...
    (Date:8/29/2014)... , August 29, 2014 ... Market by Product & Services (Equipment, Reagent, Primer, ... Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, ... MarketsandMarkets, the global Oligonucleotide Synthesis Market is expected ... Million in 2014, growing at a CAGR of ...
    Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
    ... Compare Genous vs. Drug-Eluting and Bare ... ... in the,randomized TRIAS (TRI-stent Adjudication Study) trial of OrbusNeich,s,Genous Bio-engineered R ... April, according to Robbert de Winter, M.D., Ph.D.,principal investigator and director ...
    ... 16 Protocol Driven Healthcare,Inc. (PDHI) today ... Hallmark Insights to provide fully integrated incentive ... ConXus health improvement platform. ConXus Rewards ... points earned by participants completing activities within ...
    Cached Medicine Technology:Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) 2PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs 2
    (Date:8/31/2014)... August 31, 2014 Healthy Grid ... cavities. Loloz lollipops will use herbs to fight ... hard candies will also fight bacteria while stimulating saliva production. ... together,” said Andrew Clapp of Healthy Grid. “Even though personal ... can always use a little more prevention. Cavities are painful ...
    (Date:8/31/2014)... CO (PRWEB) August 31, 2014 ... released award winning, “Simplicity & Sophistication: Short Stories ... written and narrated by Dr. James W. Jackson author, ... Sophistication,” Dr. Jackson compresses his vast volume ... four decades into over 150 countries on behalf of ...
    (Date:8/31/2014)... 2014: Renal denervation seems to be more successful at ... it includes accessory renal arteries, according to research presented ... Germany. , Dr Schmiedel said: "More than one billion ... as blood pressure (BP) greater than 140/90 mmHg. Up ... and are unable to reduce BP below 140/90 mmHg ...
    (Date:8/30/2014)... Sunday 31 August 2014: Local anaesthetic is as safe ... general anaesthetic, according to results of the FRANCE 2 ... Chopard from France. , Dr Chopard said: "Numerous studies ... for patients with severe symptomatic aortic stenosis who are ... aortic valve replacement. The number of TAVI procedures in ...
    (Date:8/30/2014)... Not only is USHEALTH Advisors now on pace ... its highest level of late-summer sales, including a new company ... to set a new record in 2014,” stated USHEALTH Advisors ... in both weekly annualized volume and the amount of writing ... August, we saw even more of our agents enjoying tremendous ...
    Breaking Medicine News(10 mins):Health News:Healthy Grid: Fight Cavities With Sweet Treats 2Health News:Healthy Grid: Fight Cavities With Sweet Treats 3Health News:Brook Forest Voices Announces End of Summer Release! Dr. James Jackson’s, “Simplicity & Sophistication” Audiobook 2Health News:Renal denervation more successful when it includes accessory arteries 2Health News:Local anesthetic for TAVI as safe and effective as general anesthetic 2Health News:USHEALTH Advisors, LLC Continues Its Record-Setting Sales Pace 2
    ... For his dedication to advancing the diversity of doctoral-level ... the American Association for the Advancement of Science (AAAS) ... DeSimonewho serves as both the Chancellor,s Eminent Professor of ... Hill (UNC), and as the William R. Kenan, Jr. ...
    ... (BWH) was selected by the Centers for Medicare & ... a demonstration project that promotes appropriate utilization of advanced ... was selected as a convener under the Medical Imaging ... Medical Center-Physician Hospital Organization; University of Wisconsin Hospital Foundation, ...
    ... Amanda Gardner HealthDay Reporter , WEDNESDAY, Feb. 16 ... state-of-the-nation,s health report and the news is mixed, with life ... On the positive side, life expectancy was up slightly ... beginning of the decade. And while women are still ...
    ... the unpredictable economy, nearly three-quarters (73%) of New Jersey ... globally is important to jobs and incomes in the ... Research!America. The poll data will be released today at ... research and development (R&D) experts and New Jersey business, ...
    ... (HealthDay News) -- Americans living in parts of Appalachia ... active in their free time, according to federal government ... least likely to be physically active during leisure time ... inactivity rates are 29.2 percent or greater for more ...
    ... , WEDNESDAY, Feb. 16 (HealthDay News) -- Many American parents ... and cold medicines to their kids despite U.S. Food and ... In response to research linking over-the-counter (or OTC) cough and ... ages 2 years and younger, the FDA said in 2008 ...
    Cached Medicine News:Health News:2010 AAAS Mentor Award goes to Dr. Joseph M. DeSimone of the University of North Carolina at Chapel Hill, and North Carolina State University 2Health News:2010 AAAS Mentor Award goes to Dr. Joseph M. DeSimone of the University of North Carolina at Chapel Hill, and North Carolina State University 3Health News:2010 AAAS Mentor Award goes to Dr. Joseph M. DeSimone of the University of North Carolina at Chapel Hill, and North Carolina State University 4Health News:Brigham and Women's Hospital selected to participate in Medicare imaging demonstration project 2Health News:Brigham and Women's Hospital selected to participate in Medicare imaging demonstration project 3Health News:America's Health a Mixed Bag: Report 2Health News:America's Health a Mixed Bag: Report 3Health News:Most New Jersey residents see global health as critical to state's economy 2Health News:Most New Jersey residents see global health as critical to state's economy 3Health News:Appalachia, the South Home to Least-Active Americans: CDC 2Health News:Parents Still Giving Cough, Cold Meds to Kids Under 2: Poll 2
    ... A product you can trust its ... perform retinal, cataract, and glaucoma therapy ... III Combi is the optimal system ... and combined iridotomy. The push of ...
    ... YAG III is the new disruption ... in particular for applications in posterior ... the YAG laser is also used ... IOL polishing. It's another milestone in ...
    ... is a top quality Carl Zeiss Meditec ... vision defects even safer, more patient-friendly and ... work platform are oriented towards increasing efficiency, ... recovery of vision. Key factors here are ...
    An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
    Medicine Products: